Welcome to our new website. We have rebranded from Atnahs to Pharmanovia — read more
Pharmanovia Promotes Alessandro Insalata to Chief Commercial Officer
Basildon (UK), 3 June 2021 – Pharmanovia, the original medicines specialist globally announced the promotion of...
More informationThe Original Medicines Specialist Rebrands to Pharmanovia
Basildon (UK), 4 May 2021 – Atnahs, the original medicines specialist backed by PE investor Triton Partners,...
More informationAtnahs Appoints New Chief Financial Officer
Basildon (UK), 22 March 2021 – Atnahs has appointed Felipe Florez to the position of Chief Financial...
More informationAtnahs Acquires Rights to Valium®
Basildon (UK), 1 December 2020 – Atnahs (“Atnahs”), has acquired the commercial rights for Valium® (Diazepam) in...
More informationCOVID-19: Atnahs Continues Operations
Basildon (UK), 19 March 2020 – On 11 March 2020 the World Health Organization (WHO) declared...
More informationAtnahs Acquires Rights to Rocaltrol®, An Established Brand in Women’s Health
Basildon (UK) / Basle (Switzerland), 19 March 2020 – Atnahs (“Atnahs”), a Triton Fund V portfolio company,...
More informationAtnahs Buys Takeda Out of License Agreement for Bonviva® in Asia
Basildon (UK), 6 February 2020 – Atnahs has bought Takeda out of a license agreement for...
More informationAtnahs Acquires Rights to Established Hypertension Medicines
Basildon / Cambridge (UK), 27 January 2020 – Atnahs, a Triton Fund V portfolio company, has signed...
More informationTriton Completes Acquisition of a Majority Stake in Atnahs
Frankfurt (Germany), Basildon (United Kingdom), August 8, 2019 – Funds advised by Triton have successfully completed...
More information